 LIBERTY 1 and LIBERTY 2 achieved 73.4 and 71.2 response rates in menstrual blood loss, with an average reduction of 84.3 from baseline Achieved six of seven key secondary endpoints including reduction of pain Bone mineral density maintained at levels comparable to placebo Data were included in U.S. New Drug Application for relugolix combination tablet for uterine fibroids LIBERTY 1 and LIBERTY 2 achieved 73.4 and 71.2 response rates in menstrual blood loss, with an average reduction of 84.3 from baseline Achieved six of seven key secondary endpoints including reduction of pain Bone mineral density maintained at levels comparable to placebo Data were included in U.S. New Drug Application for relugolix combination tablet for uterine fibroids 